COVID-19 (Coronavirus) Update: Testing and Information | Vaccine Updates | Visitor Guidelines

Treatment Free Remission After Combination Therapy with Ruxolitinib Plus Tyrosine Kinase Inhibitors in Chronic Phase Chronic Myeloid Leukemia (CP-CML) Patients Who Relapsed After a Prior Attempt at TKI Discontinuation

Protocol No
HJKC3-0002
Principal Investigator
Ehab Atallah
Phase
II
Summary
Recently, clinical trials have looked at patients who are attempting to stop TKI medications for a second time after relapsing during their first stopping attempt. These studies have shown that it is possible to stop a second time and be monitored for recurrence. The purpose of this study is to determine if adding ruxolitinib to a TKI prior to a second attempt at stopping a TKI will lead to prolonged treatment free remission.
Description
Treatment Free Remission After Combination Therapy With Ruxolitinib Plus Tyrosine Kinase Inhibitors
Participating Institutions
OHSU - Oregon Health & Science University Knight Cancer Institute
Memorial Sloan Kettering Cancer Center - Bergen
Moorland Reserve Health Center
Froedtert Hospital
Fred Hutchinson Cancer Research Center
Roswell Park Cancer Institute
Memorial Sloan Kettering Cancer Center
Moffitt Cancer Center University of South Florida
Status
OPEN TO ACCRUAL